

March 13, 2020

Guidance to Researchers Regarding Determination of whether a human research visit should take place onsite at UC Davis during the COVID-19 outbreak.

The following examples are provided as a guide to help principal investigators, participants, and participant care providers determine suitability of in-person research visits. These determinations and the balance of potential benefits and harms will vary by study objectives, target patient population, and may change as the COVID-19 outbreak evolves. These examples are not intended to be comprehensive of all study types and it is up to the investigators and/or treating healthcare providers to determine if potential benefits outweigh the risk of an onsite visit.

Question about this guidance may be directed to the UC Davis IRB

(<https://research.ucdavis.edu/contact-us/irb/>), the CTSC Medical Director Daniel Nishijima, MD, MAS (dnishijima@ucdavis.edu) or the CTSC PI Ted Wun, MD (twun@ucdavis.edu)

For these study designs:	Is the specific research visit " <u>essential to the health and/or well-being</u> " of the participant, thus supporting in-person visits?		
	These visit types are LIKELY "essential" (supports an in-person visit)	These visit types may or may not be "essential" (Support for in-person visit will depend on specifics of the study)	These visit types are LIKELY not "essential" (does not support an in-person visit)
Randomized controlled efficacy trial (e.g., phase IIb or III) of a potential drug or device or other intervention	<ul style="list-style-type: none"> New enrollments Follow ups 		
Post-approval trial (e.g., phase IV) of a therapeutic drug, device, or other intervention to assess tolerability and/or long-term benefit	<ul style="list-style-type: none"> Follow ups 	<ul style="list-style-type: none"> New enrollments 	
Early phase (e.g., phase I or IIa) pharmacodynamic, safety, tolerability or feasibility trial of a potential drug or device or other intervention	<ul style="list-style-type: none"> Follow ups 	<ul style="list-style-type: none"> New enrollments 	
Non-randomized interventional trial of a drug, device, or other intervention requiring safety monitoring	<ul style="list-style-type: none"> Follow ups 	<ul style="list-style-type: none"> New enrollments 	
Non-randomized interventional trial of a drug, device, or other intervention not requiring safety monitoring		<ul style="list-style-type: none"> New enrollments Follow ups 	
Comparative effectiveness studies or other study types describing the natural history of disease or other clinical outcomes		<ul style="list-style-type: none"> Follow ups 	<ul style="list-style-type: none"> New enrollments
Non-interventional qualitative study			<ul style="list-style-type: none"> New enrollments Follow ups
Non-interventional study with collection of clinical data and/or biological specimens for future research			<ul style="list-style-type: none"> New enrollments Follow ups

(adapted from UCSF guidance 11 March 2020)